Title | Agios’s Mitapivat (AG348) Mechanism of Action- Mellalta Meets findings |
URL | https://mellalta.com/agioss-pkr-activator-mitapivats-strategy-for-sickle-cell-disease-scd/ |
Category | Fitness Health --> Conditions and Diseases |
Meta Keywords | Hemolytic anemia; Pyruvate kinase deficiency; Red Cell Enzyme Abnormalities; Red Cells; Treatment of pyruvate kinase deficiency, Agio pharmaceutical, EHA, Sickle cell disease, SCD, USFDA, PKR
Thalassemia
|
Meta Description | Mitapivat (AG348) Mechanism of Action |
Owner | Emma Stones |
Description |
Agios Pharmaceuticals, shared the proof of clinical concept that has been established based on preliminary analysis in the phase 1 study of mitapivat (AG-348) in patients with sickle cell anemia. |